•  
  •  
 

The Science Journal of the Lander College of Arts and Sciences

Authors

Abstract

Acute promyelocytic leukemia (APL) is an oncological emergency primarily due to hemorrhage, often resulting in early death. High survival rates are seen in patients treated with all trans retinoic acid (ATRA) if initiated promptly; hence, rapid identification of APL is crucial in being able to prevent early death. This paper analyzes whether electrochemical DNA biosensors can help address the current diagnostic limitations that contribute to delayed initiation of ATRA therapy. The research utilized in analyzing this paper was acquired mainly from Touro University Online Libraries. APL occurs when there is a gene transfer between chromosomes 15 and 17, creating the PML-RARα fusion gene. Normally, the promyelocytic leukemia gene (PML) encodes proteins that form a protein structure known as a nuclear body, which helps with transcription and apoptosis. Retinoic acid receptor alpha (RARα) forms a heterodimer with retinoid X receptor alpha (RXRα) to promote the differentiation of promyelocytes in healthy cells. A variety of tests are available to assist in diagnosing APL, each with its own role in diagnosis. Tests that raise clinical suspicion include complete blood counts (CBC) and peripheral smears, which offer rapid results and are widely accessible; immunophenotyping can further raise suspicion but requires an advanced laboratory setup. Real-time quantitative polymerase chain reaction (RT-qPCR), fluorescence in situ hybridization (FISH), and karyotyping provide accurate genetic confirmation but are limited by turnaround time and accessibility in lower-resource health care settings. Electrochemical DNA biosensors offer the potential to address these limitations by providing accurate, rapid, and accessible testing. The main limitation in utilizing biosensors for diagnostic purposes is the lack of available clinical data in patient populations. Thus, implementing clinical trials would be the next step to aid in using biosensors as a valuable tool for early diagnosis and treatment of APL, and in turn, reduce mortality.

Request Accessible Format
Need this file in a format that works better with assistive technology? Submit a request.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.